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Optimizing Long-Term Antithrombotic Therapy After
Acute Coronary Syndrome*Christian T. Ruff, MD, MPHSEE PAGE 777A cute coronary syndrome (ACS) is associatedwith substantial morbidity and mortality(1,2). Initial treatment in the hospital con-
sists of intensive antithrombotic therapy combining
parenteral anticoagulation with antiplatelet therapy,
whereas secondary prevention relies primarily on
dual antiplatelet therapy (DAPT), most commonly
aspirin and clopidogrel. However, patients with
ACS remain at signiﬁcant risk of recurrent adverse
cardiovascular events (3). Mitigation of this risk
requires a delicate balance between escalation of
antithrombotic therapy to reduce ischemic events,
while hoping the increase in bleeding is tolerable.
This has been successful with regard to platelet in-
hibition, as substituting clopidogrel for the more
potent P2Y12 receptor antagonists, prasugrel and
ticagrelor, reduces cardiovascular death, myocardial
infarction (MI), and stroke in patients with ACS,
at the expense of increasing major spontaneous
bleeding (4,5). Regardless of the DAPT regimen,
there remains a 9% to 11% risk of an adverse car-
diovascular event within 1 year of ACS (3–5). This
forces a broader consideration of where to intervene
in the complex hemostatic interplay between the
vascular endothelium, platelets, and the coagula-
tion cascade to improve outcomes in patients with
ACS (6).
Should long-term anticoagulation play a role in the
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elevated months after an event (6,7). Data from a
meta-analysis, informed primarily by the WARIS II
(Warfarin, Aspirin, Reinfraction Study II) and
ASPECT-2 (Antithrombotics in the Secondary Pre-
vention of Events in Coronary Thrombosis-2) trials,
showed that addition of warfarin to aspirin post-ACS
reduces recurrent MI (8–10), but at the cost of sig-
niﬁcant excess major bleeding. Given the safety
concerns and difﬁculties and dangers associated with
warfarin use in clinical practice, there has been little
enthusiasm for incorporating long-term anti-
coagulation in the routine care of ACS patients.The emergence of the nonvitamin K oral anti-
coagulant agents (NOACs) has renewed interest in
the potential of long-term anticoagulation. In pa-
tients with atrial ﬁbrillation (AF), NOACS signiﬁ-
cantly reduce stroke and all-cause mortality, with
similar protection from MI compared with warfarin
(11). Importantly, NOACs are accompanied by mark-
edly less serious bleeding, particularly intracranial
hemorrhage. A critical question is whether this
favorable risk/beneﬁt proﬁle translates to patients
post-ACS. In this issue of the Journal, Hess et al. (12)
present an important subgroup analysis from the
APPRAISE-2 (Apixaban for Prevention of Acute
Ischemic Events 2) trial with the factor Xa inhibitor
apixaban to help inform this issue.
APPRAISE-2 was a double-blind, placebo-controlled
trial that randomized patients with ACS to apixaban
(5 mg, or 2.5 mg for patients who qualiﬁed for dose
reduction) versus placebo (13). At the data safety
monitoring committee’s recommendation, APPRAISE-
2 was stopped prematurely due to signiﬁcant excess
bleeding without any observed reduction in ischemic
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789events. In this study, Hess et al. (12) evaluated whether
the relative efﬁcacy and safety of apixaban com-
pared with placebo varied by concomitant anti-
platelet therapy (aspirin alone vs. DAPT with aspirin
plus clopidogrel). Regardless of background anti-
platelet therapy, apixaban had no apparent beneﬁt
in reducing cardiovascular death, MI, and ischemic
stroke compared with placebo, but there was a sig-
niﬁcant excess in Thrombolysis In Myocardial In-
farction (TIMI) major bleeding. The authors should
be credited for acknowledging the signiﬁcant limi-
tations of this study—most notably, a post-hoc sub-
group analysis of a trial that was terminated early
and almost certain residual confounding due to
the markedly different baseline characteristics and
post-randomization variables between patients
prescribed single versus dual antiplatelet therapy.
The authors did use extensive statistical measures
to mitigate these concerns, including multivari-
able adjustment for covariates associated with the
propensity to use aspirin or aspirin plus clopi-
dogrel, and a time-dependent analysis to account
for the actual antiplatelet regimen taken during
follow-up, which is important because 19.2% of
patients switched antiplatelet regimens after
randomization.
Does a “negative” substudy of a “negative” trial
add to our ability to optimize long-term antith-
rombotic therapy in patients after ACS? The answer
is a deﬁnitive “yes.” This analysis helps us to con-
textualize and reconcile the results of APPRAISE-2
with other important ﬁndings in this ﬁeld, particu-
larly in relation to the WOEST (What Is the Optimal
Antiplatelet & Anticoagulant Therapy in Patients
With Oral Anticoagulation and Coronary Stenting)
and ATLAS ACS 2-TIMI 51 (Anti-Xa Therapy to Lower
Cardiovascular Events in Addition to Standard
Therapy in Subjects with Acute Coronary Syndrome 2-
Thrombolysis In Myocardial Infarction 51) trials
(14,15). The open-label WOEST trial randomized pa-
tients undergoing percutaneous coronary interven-
tion (only 25% to 30% with ACS) with an indication
for long-term anticoagulation (most for AF) to triple
therapy with warfarin, aspirin, and clopidogrel or
double therapy with warfarin and clopidogrel (14).
Not surprisingly, dropping aspirin resulted in a
>50% reduction in bleeding complications. More
interestingly, double therapy was associated with a
signiﬁcant reduction in a broad composite of adverse
cardiac and cerebrovascular events. How can a less
potent antithrombotic regimen more effectively
prevent ischemic events? By causing less bleeding:
ﬁrst, bleeding leads to discontinuation of both anti-
coagulant and antiplatelet therapy, so patients losethe ischemic protection afforded by those agents;
second, bleeding results in a prothrombotic inﬂam-
matory state that further increases the risk of an
ischemic event. A recent study of apixaban in AF
demonstrated that bleeding (nonintracranial hemor-
rhage) was independently associated with a 12-fold
excess of risk of death, ischemic stroke, or MI (16).
Why was there an advantage to single-antiplatelet
therapy in combination with warfarin in WOEST,
but not to apixaban in APPRAISE-2? These trials are
fundamentally different in that all patients in
WOEST received warfarin because they had another
indication for anticoagulation. WOEST tested
whether we can optimize obligate full-dose anti-
coagulation in patients who also require antiplatelet
therapy. In contrast, APPRAISE-2 tested whether it is
possible to safely add optional full-dose anti-
coagulation for patients who require antiplatelet
therapy. It is reasonable to conclude that if a patient
with ACS requires full-dose anticoagulation for
another indication, a less potent antiplatelet strategy
may offer the best net clinical beneﬁt, but there
seems to be no role for full-dose long-term anti-
coagulation speciﬁcally for ACS.
The results of ATLAS ACS 2-TIMI 51 demon-
strated that lower doses of rivaroxaban, 2.5 mg
and 5 mg twice daily (full-dose: 20 mg once daily)
in patients with ACS were associated with re-
ductions in cardiovascular death, MI, and stroke
compared with placebo (15). Both regimens were
associated with excess bleeding. Why was rivarox-
aban effective in reducing hard cardiovascular out-
comes compared with placebo in patients with ACS,
despite receiving triple therapy (almost all patients
were on aspirin and clopidogrel), whereas there
was no apparent beneﬁt with apixaban, even in
patients taking only aspirin? The dose, not the
speciﬁc anticoagulant, is most likely the critical
factor. The rivaroxaban doses tested in ACS were
one-fourth to one-half of those tested for the
AF and venous thromboembolism indication, sug-
gesting a possible threshold effect when using
anticoagulation in combination with antiplatelet
therapy for ACS. Some suppression of the coagula-
tion pathway is helpful, but too much exposes
patients to unacceptable rates of bleeding and also
diminished efﬁcacy. Additional evidence from
ATLAS ACS 2-TIMI 51 supports this premise: the
2.5-mg dose of rivaroxaban signiﬁcantly reduced
cardiovascular and all-cause mortality, but not the
5-mg dose. On this basis, rivaroxaban 2.5 mg was
approved by the European Medicine Agency, but
not by the U.S. Food and Drug Administration,
for patients with recent ACS.
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790The results of this subanalysis of the APPRAISE-2
trial further clarify the existing data that full-dose
anticoagulation, in combination with antiplatelet
therapy of any kind in patients with ACS, results
in substantial bleeding without any clear addi-
tional beneﬁt and should only be considered when
required for another condition. How to optimize
such an antithrombotic regimen, especially in
light of the myriad of new options, including
4 approved NOACs and the more potent antiplatelettherapies (prasugrel, ticagrelor, vorapaxar) not
included in the previously mentioned studies, is
critically important and the subject of ongoing
investigation.
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